Premium
FIRST‐LINE GEFITINIB, ERLOTINIB, AND AFATINIB PROVIDED SIMILAR CLINICAL EFFICACY IN PATIENTS WHO HAD STAGE IV LUNG ADENOCARCINOMA HARBORING RARE EGFR MUTATION IN TAIWAN
Publication year - 2018
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.13420_563
Subject(s) - afatinib , gefitinib , erlotinib , medicine , oncology , stage (stratigraphy) , adenocarcinoma , lung cancer , second line , mutation , lung , adenocarcinoma of the lung , epidermal growth factor receptor , first line , cancer , genetics , paleontology , gene , biology